/PRNewswire/ OnQuality Pharmaceuticals ("OnQuality"), an oncology company developing targeted supportive therapies to address unmet needs in oncodermatology.
Benjamin Kaffenberger
On the new Prognosis Ohio, part of the WCBE Podcast Experience, Dan Skinner talks with OSU dermatologist and researcher, Benjamin Kaffenberger, MD, about a study he is leading to develop new drugs that aim to relieve cancer patients of pain caused by cancer treatments, known as Hand-Foot Skin Reaction .
Topics include cancer care, dermatology and its relationship with oncology, the cost of pharmaceuticals, and more.
On the show, Skinner and Kaffenberger address the clinical trial Kaffenberger is leading. You can read up on Hand-Foot Skin Reaction here and Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) here. For information on the Pharma startup that is leading these efforts, you can check the OnQuality website, especially their pipeline. For information on the NIH funding, go here.